Insilco molecular docking study of Dihydroisoquinolinium Derivatives as DPP IV Inhibitors in Type II Diabetes Mellitus
Keywords:
Docking, DPP IV, Autodock vina, Insilco, Dihydroisoquinolinium, Type II Diabetes
Abstract
With the spread of western lifestyles, the occurrence of diabetes in the world’s population is rising. Diabetes is a complex metabolic endocrine disorder that occurs when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin it produces. It is classified into two basic forms Type I and Type II diabetes. A major goal for the treatment of type II diabetes is the enhancement of insulin secretion by pancreatic islet b-cells.
References
1.Sokeng, S.D., D. Lontsi, P.F. Moundipa, H.B. Jatsa, P. Watcho and P. Kamtchouing, 2007. Hypoglycemic Effect of AnacardiumoccidentaleL.Methanol Extract and Fractions on Streptozotocin-induced Diabetic Rats. Global Journal of Pharmacology, 1(1): 01-05.
2.Baquer, N.Z., D. Gupta and J. Raju, 1998. Regulation of metabolic pathways in liver and kidney during experimental diabetes. Effects of antidiabetic compounds. Indian J Clinical Biochem, 13: 63-80.
3. Visweswara Rao, P. and M. Dhananjaya Naidu, 2010. Anti Diabetic Effect of Rhinacanthusnasutus Leaf Extract in Streptozotocin Induced Diabetic Rats. Libyan Agriculture Research Center Journal International, 1(5): 310-312.
4.Grijesh Kumar Mall, PankajKishor Mishra and Veeru Prakash, 2009. Antidiabetic and Hypolipidemic Activity of Gymnemasylvestre in Alloxan Induced Diabetic Rats. Global Journal of Biotechnology and Biochemistry, 4(1): 37-42.
5.Baquer, N.Z., D. Gupta and J. Raju, 1998. Regulation of metabolic pathways in liver and kidney during experimental diabetes. Effects of antidiabetic compounds. Indian J. Clinical Biochem, 13: 63-80.
6. EilyadIssabeagloo, Reza forughi, Mohammed Taghizadieh and ParvizKermanizadeh, 2012. Effect of Alcohol on Blood Glucose Levels in Streptozotocin Induced Diabetic Rats. Middle-East Journal of Scientific Research, 12(3): 290-293.
7. Mohammad Yaheya Mohammad Ismail, 2009. Clinical Evaluation of Antidiabetic Activity of Trigonella Seeds and Aeglemarmelos Leaves, World Applied Sciences Journal, 7(10): 1231-1234.
8. NisarZamin Shah, Naveed Muhammad, SadiaAzeem and AbdurRauf, 2013.Hypoglycemic Effect of Crude Methanolic Extract as Well as Sub Fractions of Morusalba on Rabbits. Global Journal of Pharmacology, 7(1): 91-94.
9. International Diabetes Federation. The IDF Diabetes Atlas. Fifth Edition. Brussels: International Diabetes Federation, 2011.
10. Chao, E.C. and R.R. Henry, 2010. SGLT2 inhibition-a novel strategy for diabetes treatment. Nat. Rev. Drug. Discov, 9: 551-559.
11. ManmohanSinghal, ShaileeRasania, Amit Gaur, Manchireddy Vishnu, V.R. Vijaya Rama Raju and S. YozanaUpadhyay, 2012. Overview on Sodium Glucose Transport Inhibitors as a Therapeutic Tool against Diabetes Mellitus. Global Journal of Pharmacology, 6(2): 86-93.
12. Lambeir, A.M., C. Durinx, Scharpe and S. De Meester, 2003. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci., 40: 209-294.
13. Wu, X.D., H.J. Deeb, R. Singh and N. Sedkova, 2001. Depot-Specific Variation in Protein-Tyrosine phosphatase activities in human mentaland Subcutaneous adipose tissue: A Potential Contribution to Differential Insulin Sensitivity. J. ClinEndocrinolMetab, 86: 5973-5980.
14. Susie Chang, Marjorie J. Rosenberg, Holmes Morton, Clair A. Francomano and Leslie G. Biesecker, 1998. Identification of a mutation in liver glycogen phosphorylase in glycogen storage disease type VI. Hum Mol Genet, 7: 142-145.
15. Basu, R., A. Basu, C.M. Johnson, W.F. Schwenk and R.A. Rizza, 2004. Insulin dose response curves for stimulation of splanchnic glucose uptake and suppression of endogenous glucose production differ in non-diabetic humans and are abnormal in people with type 2 diabetes mellitus. Diabetes, 53: 2042-2050.
16. Pearson, S.L., M.A. Cawthorne, J.C. Clapham, S.J. Dunmore, S.D. Holmes, G.B. Moore, S.A. Smith and M. Tadayyon, 1996. The thiazolidinedione insulin sensitiser, BRL 49653, increases the expression of PPAR-gamma and aP2 in adipose tissue of high-fat-fed rats. BiochemBiophys Res Commun, 229(3): 752-757.
17.Istvan, E.S., M. Palnitkar, S.K. Buchanan and J. Deisenhofer, 2000. Crystal structure of the catalytic portion of human HMG-CoA reductase: insights into regulation of activity and catalysis. EMBO J, 19: 819- 830.
18. Abbott CA, Yu DMT, Woollatt E, Sutherland GR, McCaughan GW, Gorrell MD. Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur J Biochem. 2000; 67: 6140-50.
19. Weber AE. Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. J Med Chem. 2004; 47: 4135-41.
20. Mest HJ, Mentlein R. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia 2005; 48: 616-20.
21. Fredenrich A, Palle S, Canivet B. Dipeptidyl peptidase inhibitors: A new step towards normoglycemia. Open
Endocrinol J. 2009; 3: 16-21.
22. Biftu, T., G. Scapin, S. Singh, D. Feng, J.B. Becker, G. Eiermann, H. He, K. Lyons, S. Patel, A. Petrov, R. Sinha-Roy, B. Zhang, J. Wu, X. Zhang, G.A. Doss, N.A. Thornberry and A.E. Weber, 2007. (3R)-4-[(3R)- 3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2- trifluoroethyl)-1,4-diazepan-2-one,a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorg. Med ChemLett, 17: 49-52.
23. Trott O & Olson AJ, J Comput Chem. 2010; 31(2): 455-61
2.Baquer, N.Z., D. Gupta and J. Raju, 1998. Regulation of metabolic pathways in liver and kidney during experimental diabetes. Effects of antidiabetic compounds. Indian J Clinical Biochem, 13: 63-80.
3. Visweswara Rao, P. and M. Dhananjaya Naidu, 2010. Anti Diabetic Effect of Rhinacanthusnasutus Leaf Extract in Streptozotocin Induced Diabetic Rats. Libyan Agriculture Research Center Journal International, 1(5): 310-312.
4.Grijesh Kumar Mall, PankajKishor Mishra and Veeru Prakash, 2009. Antidiabetic and Hypolipidemic Activity of Gymnemasylvestre in Alloxan Induced Diabetic Rats. Global Journal of Biotechnology and Biochemistry, 4(1): 37-42.
5.Baquer, N.Z., D. Gupta and J. Raju, 1998. Regulation of metabolic pathways in liver and kidney during experimental diabetes. Effects of antidiabetic compounds. Indian J. Clinical Biochem, 13: 63-80.
6. EilyadIssabeagloo, Reza forughi, Mohammed Taghizadieh and ParvizKermanizadeh, 2012. Effect of Alcohol on Blood Glucose Levels in Streptozotocin Induced Diabetic Rats. Middle-East Journal of Scientific Research, 12(3): 290-293.
7. Mohammad Yaheya Mohammad Ismail, 2009. Clinical Evaluation of Antidiabetic Activity of Trigonella Seeds and Aeglemarmelos Leaves, World Applied Sciences Journal, 7(10): 1231-1234.
8. NisarZamin Shah, Naveed Muhammad, SadiaAzeem and AbdurRauf, 2013.Hypoglycemic Effect of Crude Methanolic Extract as Well as Sub Fractions of Morusalba on Rabbits. Global Journal of Pharmacology, 7(1): 91-94.
9. International Diabetes Federation. The IDF Diabetes Atlas. Fifth Edition. Brussels: International Diabetes Federation, 2011.
10. Chao, E.C. and R.R. Henry, 2010. SGLT2 inhibition-a novel strategy for diabetes treatment. Nat. Rev. Drug. Discov, 9: 551-559.
11. ManmohanSinghal, ShaileeRasania, Amit Gaur, Manchireddy Vishnu, V.R. Vijaya Rama Raju and S. YozanaUpadhyay, 2012. Overview on Sodium Glucose Transport Inhibitors as a Therapeutic Tool against Diabetes Mellitus. Global Journal of Pharmacology, 6(2): 86-93.
12. Lambeir, A.M., C. Durinx, Scharpe and S. De Meester, 2003. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci., 40: 209-294.
13. Wu, X.D., H.J. Deeb, R. Singh and N. Sedkova, 2001. Depot-Specific Variation in Protein-Tyrosine phosphatase activities in human mentaland Subcutaneous adipose tissue: A Potential Contribution to Differential Insulin Sensitivity. J. ClinEndocrinolMetab, 86: 5973-5980.
14. Susie Chang, Marjorie J. Rosenberg, Holmes Morton, Clair A. Francomano and Leslie G. Biesecker, 1998. Identification of a mutation in liver glycogen phosphorylase in glycogen storage disease type VI. Hum Mol Genet, 7: 142-145.
15. Basu, R., A. Basu, C.M. Johnson, W.F. Schwenk and R.A. Rizza, 2004. Insulin dose response curves for stimulation of splanchnic glucose uptake and suppression of endogenous glucose production differ in non-diabetic humans and are abnormal in people with type 2 diabetes mellitus. Diabetes, 53: 2042-2050.
16. Pearson, S.L., M.A. Cawthorne, J.C. Clapham, S.J. Dunmore, S.D. Holmes, G.B. Moore, S.A. Smith and M. Tadayyon, 1996. The thiazolidinedione insulin sensitiser, BRL 49653, increases the expression of PPAR-gamma and aP2 in adipose tissue of high-fat-fed rats. BiochemBiophys Res Commun, 229(3): 752-757.
17.Istvan, E.S., M. Palnitkar, S.K. Buchanan and J. Deisenhofer, 2000. Crystal structure of the catalytic portion of human HMG-CoA reductase: insights into regulation of activity and catalysis. EMBO J, 19: 819- 830.
18. Abbott CA, Yu DMT, Woollatt E, Sutherland GR, McCaughan GW, Gorrell MD. Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur J Biochem. 2000; 67: 6140-50.
19. Weber AE. Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. J Med Chem. 2004; 47: 4135-41.
20. Mest HJ, Mentlein R. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia 2005; 48: 616-20.
21. Fredenrich A, Palle S, Canivet B. Dipeptidyl peptidase inhibitors: A new step towards normoglycemia. Open
Endocrinol J. 2009; 3: 16-21.
22. Biftu, T., G. Scapin, S. Singh, D. Feng, J.B. Becker, G. Eiermann, H. He, K. Lyons, S. Patel, A. Petrov, R. Sinha-Roy, B. Zhang, J. Wu, X. Zhang, G.A. Doss, N.A. Thornberry and A.E. Weber, 2007. (3R)-4-[(3R)- 3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2- trifluoroethyl)-1,4-diazepan-2-one,a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorg. Med ChemLett, 17: 49-52.
23. Trott O & Olson AJ, J Comput Chem. 2010; 31(2): 455-61
Published
2017-06-01
How to Cite
[1]
Ghosh, A.K., Palit, S. and Samajdar, S. 2017. Insilco molecular docking study of Dihydroisoquinolinium Derivatives as DPP IV Inhibitors in Type II Diabetes Mellitus. PharmaTutor. 5, 6 (Jun. 2017), 22-28.
Section
Articles
